A FEARLESS EMBRACE of POTENTIAL

We are developing highly engineered, targeted therapies for patients fighting serious liver diseases

Unlocking the value of life-improving medicines

Boston Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing highly engineered therapies to transform the lives of patients who fight serious liver diseases.

Pipeline

Innovative collaborations and evidence-based decision making are core to our ways of working

We have partnered with biotechnology and pharmaceutical companies to acquire innovative drug candidates. We employ unencumbered decision making and advance only those programs that meet our stringent development hurdles.

Learn More

A Path to Value for Our Partners and Patients

We have established partnerships with the world’s leading biotechnology and pharmaceutical companies. We continue to seek new ways to leverage our model and create a path to value for our partners and patients across serious liver diseases.

Partnering

Recent News

1/5/2024

Boston Pharmaceuticals Presents Data at NASH-TAG 2024 Demonstrating Low Immunogenicity Over Time With Long-acting FGF21 Analogue, BOS-580, for MASH

12/19/2023

Boston Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, MD, PhD, as Acting Chief Medical Officer as MASH Asset BOS-580 Accelerates in Phase 2 Clinical Program

11/10/2023

Boston Pharmaceuticals Announces Positive Phase 2a Data Supporting Once-monthly Dosing With Investigational BOS-580 in NASH and Treatment Effects in Diabetic Subgroups at AASLD The Liver Meeting^® 2023

More news

We attribute our success in our pipeline to the exceptional people working at Boston Pharmaceuticals. We embrace the development of our employees and seek passionate, science-driven candidates with an intellectual curiosity for more.

Learn more